StockNews.AI
BDMD
StockNews.AI
3 hrs

Baird Medical Showcases Advanced Microwave Ablation Technology at the 2025 ACS Clinical Congress

1. BDMD is exhibiting MWA technology at ACS Clinical Congress 2025. 2. Hands-on demonstrations showcase benefits of MWA for various medical conditions. 3. Company focuses on expanding MWA applications and collaborations within the surgical community. 4. BDMD holds significant market position in the U.S. and China for MWA devices. 5. Participation indicates growth potential and commitment to innovative medical solutions.

9m saved
Insight
Article

FAQ

Why Bullish?

BDMD's visibility at a major medical event can attract interest and collaborations, boosting its market potential, similar to past cases where companies gained investment following effective demonstrations.

How important is it?

The article details BDMD's strategic participation in a high-profile medical event, indicating immediate opportunities for growth and partnership.

Why Short Term?

Immediate publicity from the event could influence BDMD's stock in the next few weeks, especially if demonstrations yield positive media coverage and interest.

Related Companies

JHHTMCWCMCUMC
, /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, is participating in the American College of Surgeons (ACS) Clinical Congress 2025 in Chicago, IL. The prestigious event is being held from October 5-7 and brings together tens of thousands of surgeons from around the world to explore the latest advancements in surgical care. ACS 2025 The ACS, established in 1913, is the world's largest and most influential organization for surgeons, boasting more than 90,000 members across 144 countries. The annual Clinical Congress serves as a key platform for discussing surgical advancements, exploring new technologies, and fostering collaboration within the medical community. Throughout the congress, Baird Medical is featuring its cutting-edge MWA devices at Booth 1061. The Company is conducting live, hands-on demonstrations showcasing the technology's precision and efficiency in treating a range of conditions, including thyroid nodules, breast disease, and liver cancer. This interactive exhibit provides surgeons and medical professionals the opportunity to experience firsthand the benefits of this minimally invasive treatment modality. Baird Medical's participation underscores its commitment to collaborating with the surgical community to advance patient care. The Company aims to engage with clinical leaders to discuss the expanding applications of MWA and its role in the future of interventional medicine. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact:Eric Huang, PR LiaisonBaird Medical Investment Holdings Ltd.Phone: +1 (888) 508-6228Email: [email protected]SOURCE BDMD WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News